Herceptin, Trastuzumab Newswire (Page 10)

Herceptin, Trastuzumab Newswire (Page 10)

Comprehensive Real-Time News Feed for Herceptin, Trastuzumab (generic). (Page 10)

Results 181 - 200 of 2,866 in Herceptin, Trastuzumab (generic)

  1. Breast Cancer Market Quadruples by 2023 at a 9.2% of Whooping CAGR; Asserts MRFRRead the original story w/Photo

    Dec 21, 2017 | SBWire

    The Global Breast Cancer Market report titled "Breast Cancer Market Research Report-Forecast to 2023? is a specialist investigation report by Market Research Future includes broad essential research alongside the definite examination of subjective and additionally quantitative perspectives by different industry specialists, key sentiment pioneers to pick up a more profound understanding of the market and industry execution. The global breast cancer market is expected to grow at a CAGR of 9.2% during forecasted period 2017-2023.

    Comment?

  2. FDA approves Roches Perjeta (pertuzumab) for adjuvant treatment of...Read the original story

    Dec 20, 2017 | PressReleasePoint

    Roche today announced the US Food and Drug Administration has approved PerjetaA , in combination with HerceptinA and chemotherapy , for adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence.1 People should receive the adjuvant Perjeta-based regimen for one year . The FDA has also converted the previously granted accelerated approval of the Perjeta-based regimen to full approval for neoadjuvant treatment of HER2-positive, locally advanced, inflammatory, or early stage breast cancer .

    Comment?

  3. CHMP Adopts Positive Opinion for Celltrion's HerzumaRead the original story w/Photo

    Dec 20, 2017 | JD Supra

    On December 16, Celltrion announced that it has received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for Herzuma, its trastuzumab biosimilar. The CHMP has recommended that Herzuma be approved for the treatment of "early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification."

    Comment?

  4. FDA Approves Genentech's Perjeta (pertuzumab) for Adjuvant Treatment...Read the original story

    Dec 20, 2017 | Customer Interaction Solutions

    Genentech, a member of the Roche Group , today announced the U.S. Food and Drug Administration has approved Perjeta , in combination with Herceptin and chemotherapy , for adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence. People should receive the adjuvant Perjeta-based regimen for one year .

    Comment?

  5. FDA OKs expanded use of Roche's Perjeta in certain type of breast cancerRead the original story w/Photo

    Dec 20, 2017 | Seeking Alpha

    The FDA approves the use of Roche unit Genentech's Perjeta , in combination with Herceptin and chemo, for the adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence. Concurrently, the agency has converted the accelerated approval for a Perjeta-based regimen in a neoadjuvant setting for HER2-positive breast cancer to full approval.

    Comment?

  6. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Dec 20, 2017 | Business Wire

    "We are pleased to introduce Steve a... )--The Board of Directors of Harleysville Financial Corporation , holding company for Harleysville Bank , announced today th... )--The "Europe Esophageal Cancer Market and Competitive Landscape - 2017" report has been added to Research and Markets' offering.

    Comment?

  7. FDA accepts Samsung Bioepis' marketing application for Herceptin biosimilarRead the original story w/Photo

    Dec 20, 2017 | Seeking Alpha

    The FDA accepts for review Samsung Bioepis' marketing application for a biosimilar of Roche's ( OTCQX:RHHBY ) breast cancer med Herceptin (trastuzumab). If approved, it will be marketed in the U.S. by joint venture partner Merck (NYSE: MRK ).

    Comment?

  8. Samsung Bioepis' SB3 Trastuzumab Biosimilar Candidate Accepted for...Read the original story w/Photo

    Dec 19, 2017 | Customer Interaction Solutions

    Bioepis Co., Ltd. today announced that the US Food and Drug Administration has accepted for review the company's Biologics License Application under the 351 pathway for SB3, a biosimilar candidate referencing Herceptin i . SB3 is Samsung Bioepis' first oncology biosimilar candidate submitted for regulatory review in the United States .

    Comment?

  9. US Biosimilar Approvals Soar in 2017Read the original story w/Photo

    Dec 19, 2017 | JD Supra

    Marketing approval for US biosimilars has taken off in 2017. FDA has approved five biosimilar products this year, increasing the number of approved biosimilars from four to nine.

    Comment?

  10. Hikma Pharmaceuticals agrees licensing deal with CelltrionRead the original story w/Photo

    Dec 19, 2017 | Live Charts

    Hikma Pharmaceuticals has reached a licensing agreement with South Korea-based Celltrion for Truxima , the first biosimilar monoclonal antibody in oncology to be granted European marketing authorisation. Hikma now has exclusive agreements with Celltrion for three biosimilar products - Truxima , Remsima and Herzuma - in all its Middle East and North Africa markets.

    Comment?

  11. Breast Cancer Market to Enlist Popularity rate at ~9.2% of CAGR from 2016 to 2027Read the original story

    Dec 19, 2017 | Emailwire.com

    This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the global Breast Cancer Market over the forecast period. The Global Breast Cancer Market report titled 'Breast Cancer Market Research Report-Forecast to 2023" is a specialist investigation report by Market Research Future includes broad essential research alongside the definite examination of subjective and additionally quantitative perspectives by different industry specialists, key sentiment pioneers to pick up a more profound understanding of the market and industry execution.

    Comment?

  12. Update on BiosimilarsRead the original story w/Photo

    Dec 18, 2017 | jdsupra.com

    In November 2016, Health Canada issued a Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs . In March 2017, Health Canada held a Biosimilars Workshop and issued a report , which notes that Health Canada intends to consult with stakeholders about the impact of naming of biosimilars on prescribing, dispensing and pharmacovigilance needs.

    Comment?

  13. 3 Things In Biotech You Should Learn Today: December 17, 2017Read the original story w/Photo

    Dec 17, 2017 | Seeking Alpha

    Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. News: PBYI announced that the EMA has requested a Scientific Advisory Group on Oncology to discuss the clinical aspects of its application for approval in Europe for neratinib in the "extended adjuvant" setting for early-stage HER2-positive breast cancer.

    Comment?

  14. Critical Review: Oncobiologics (ONS) & Its RivalsRead the original story w/Photo

    Dec 16, 2017 | AmericanBankingNews.com

    Oncobiologics is one of 184 public companies in the "Biotechnology & Medical Research" industry, but how does it contrast to its competitors? We will compare Oncobiologics to similar businesses based on the strength of its valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership. Oncobiologics presently has a consensus target price of $9.00, suggesting a potential upside of 675.86%.

    Comment?

  15. Celltrion Receives Positive CHMP Opinion for Herzuma for Trastuzumab BiosimilarRead the original story

    Dec 15, 2017 | Customer Interaction Solutions

    Celltrion, Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending that Herzuma be granted marketing authorization in the European Union for the treatment of patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification. The CHMP's opinion will now be sent to the European Commission for final review.

    Comment?

  16. Study protocol of HGCSG1404 SNOW study: a phase I/II trial of...Read the original story w/Photo

    Dec 7, 2017 | BioMed Central

    In Japan, S-1 plus cisplatin regimen has become a standard therapy for patients with advanced gastric cancer. Moreover, the S-1 plus oxaliplatin regimen is now a standard treatment.

    Comment?

  17. Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with...Read the original story

    Dec 7, 2017 | PressReleasePoint

    Updated analysis from an ongoing phase 1 study of DS-8201 demonstrated a confirmed overall response rate of 61.4 percent and disease control rate of 94.7 percent in patients with HER2-positive metastatic breast cancer pre-treated with ado-trastuzumab emtansine Preliminary results from the same study of DS-8201 demonstrated a confirmed overall response rate of 31.6 percent and disease control rate of 84.2 percent in an analysis of heavily pretreated patients with HER2 low-expressing metastatic breast cancer af Pivotal phase 2 DESTINY-Breast01 study of DS-8201 is currently enrolling patients with HER2-positive metastatic breast cancer resistant and refractory to T-DM1 Tokyo, Basking Ridge, NJ, and Munich - - Daiichi Sankyo Company, Limited today announced that updated safety and efficacy data from two subgroups of patients with metastatic breast cancer from an ongoing phase 1 study of ... (more)

    Comment?

  18. IPR UpdatesRead the original story w/Photo

    Dec 7, 2017 | JD Supra

    On December 1, 2017, the Board granted institution of four IPRs on Celltrion's petitions and Pfizer's petitions challenging Genentech's Carter patent, U.S. Patent No. 6,407,213, directed to humanized antibodies.

    Comment?

  19. Prolonged Progression-Free Survival Reinforces Tucatinib's Potential...Read the original story

    Dec 7, 2017 | Customer Interaction Solutions

    Cascadian Therapeutics, Inc. , a clinical-stage biopharmaceutical company, today announced that tucatinib in combination with standard of care agents demonstrated prolonged progression-free survival in a subgroup of patients participating in two ongoing Phase 1b studies. Results from a subgroup analysis from these tucatinib combination studies showed 22 percent of patients with HER2-positive metastatic breast cancer with and without brain metastases achieved prolonged PFS defined as twice the median PFS seen in these studies or else defined as survival greater than 17 months.

    Comment?

  20. In situ single-cell analysis identifies heterogeneity for PIK3CA...Read the original story

    Dec 7, 2017 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. Detection of minor, genetically distinct subpopulations within tumors is a key challenge in cancer genomics.

    Comment?